Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160
Tóm tắt
A replication-defective, recombinant Sindbis virus vector was utilized in a novel immunization strategy to induce humoral and cellular responses against hepatitis C virus (HCV). The recombinant vector, pVaXJ-E1E2, expressing the gene for HCV glycoproteins E2 and E1, was constructed by inserting the E1E2 gene into the replicon pVaXJ, a DNA vector derived from Sindbis-like virus XJ-160. The defective replicon particles, XJ-E1E2, were produced by transfecting BHK-21E+Capsid cells, the packaging cell lines for the vector from XJ-160 virus, with pVaXJ-E1E2. Both glycoproteins, E2 and E1, were stably expressed, as indicated by immunofluorescence assay (IFA) and Western blotting. Mice were vaccinated using a prime-boost strategy with XJ-E1E2 particles combined with Freund’s incomplete adjuvant via intramuscular injection at 0 and 2 weeks. HCV-specific IgG antibody levels and cellular immune responses were evaluated by IFA and IFN-γ ELISPOT, respectively. The results showed that the defective XJ-E1E2 particles in combination with Freund’s incomplete adjuvant induced effective humoral and cellular immune responses against HCV glycoprotein E1 or E2, suggesting that a defective Sindbis particle vaccine is capable of eliciting an effective immune response. These findings have important implications for the development of HCV vaccine candidates.
Tài liệu tham khảo
Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567
Arribillaga L, Sarobe P, Arina A, Gorraiz M, Borras-Cuesta F, Ruiz J, Prieto J, Chen L, Melero I, Lasarte JJ (2005) Enhancement of CD4 and CD8 immunity by anti-CD137 (4–1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 23:3493–3499
Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A (2006) A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 80:1688–1699
Ploss A, Dubuisson J (2012) New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 61:i25–i35
Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85:3173–3188
Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera B, Tafi R, Arcuri M, Fattori E, Lahm A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A (2006) A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12:190–197
Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659–662
Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM (2003) Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197:1645–1655
Shiina M, Rehermann B (2006) Hepatitis C vaccines: inducing and challenging memory T cells. Hepatology 43:1395–1398
Thimme R, Neumann-Haefelin C, Boettler T, Blum HE (2008) Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 389:457–467
Kirman JR, Turon T, Su H, Li A, Kraus C, Polo JM, Belisle J, Morris S, Seder RA (2003) Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71:575–579
Polo JM, Gardner JP, Ji Y, Belli BA, Driver DA, Sherrill S, Perri S, Liu MA, Dubensky TW Jr (2000) Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel) 104:181–185
Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, Romero RE, Tang Z, Bin Q, Dubensky TW, JrM Vajdy Jr, Otten GR, Polo JM (2003) An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77:10394–10403
Lin YL, Kwon T, Polo J, Zhu YF, Coates S, Crawford K, Dong C, Wininger M, Hall J, Selby M, Coit D, Medina-Selby A, McCoin C, Ng P, Drane D, Chien D, Han J, Vajdy M, Houghton M (2008) Induction of broad CD4+ and CD8+ T-Cell responses and cross-neutralizing antibodies against Hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Viro 82:7492–7503
Zhu WY, Liang GD (2009) Selection and characterization of packaging cell lines for XJ-160 virus. Intervirology 52:100–104
Zhu WY, Li JJ, Tang L, Wang HQ, Li J, Fu JJ, Liang GD (2011) Glycoprotein is enough for sindbis virus-derived DNA vector to express heterogenous genes. Virol J 8:344
Bi SL, Bai XH, Cong ME, Liu CB (1993) Sequence analysis and variation in hepatitis C virus isolate from Hebei Province, China. Chin J Virol 9:114–127
Zhu WY, Yang YL, Fu SH, Wang LH, Zhai YG, Tang Q, Liang GD (2009) Substitutions of 169Lys and 173Thr in nonstructural protein 1 influence the infectivity and pathogenicity of XJ-160 virus. Arch Virol 154:245–253
Popov VL, Chen SM, Feng HM, Walker DH (1995) Ultrastructural variation of cultured Ehrlichia chaffeensis. J Med Microbiol 43:411–421
Li C, Liu F, Liang M (2010) Hantaviruslike particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine 28:4294–4300
Guan J, Wen B, Deng Y, Zhang K, Chen H, Wu XB, Ruan L, Tan WJ (2011) Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J 8:56
Elmowalid GA, Qiao M, Jeong SH, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Muethy K, Liang TJ (2007) Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 104:8427–8432
Cocquerel L, Kuo CC, Dubuisson J, Levy S (2003) CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 77:10677–10683
Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Chéné ID, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3: 94ra71
Dahari H, Feinstone SM, Major ME (2010) Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterol 139:965–974
Nakata S, Estes MK, Chiba S (1988) Detection of human calicivirus antigen and antibody by enzyme-linked immunosorbent assays. J Clin Microbiol 26:2001–2005
Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi MK, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS (2011) Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 85:7005–7019
Mecchia M, Casato M, Tafi R, Filocamo G, Bonomo L, Fiorilli M, Cortese R, Migliaccio G, Nicosia A (1996) Nonrheumatoid IgM in human hepatitis C virus-associated type II cryoglobulinemia recognize mimotopes of the CD4-like LAG-3 protein. J Immunol 157:3727–3736